Evidence map›Paper›PMID 16714073›Full record

ArticleVaccine2006

Importance of HLA-DQ and HLA-DP polymorphisms in cytokine responses to naturally processed HLA-DR-derived measles virus peptides.

Inna G Ovsyannikova, Robert A Vierkant, Gregory A Poland

Open access · greenAbstract read
In one paragraph

Article in Vaccine, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. HLA-DR: molecular insights and vaccine design.Current pharmaceutical design · 2009
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Inna G OvsyannikovaMayo Vaccine Research Group, Guggenheim 611C, 200 First Street SW, Rochester, MN 55905, USA.
Robert A Vierkant
Gregory A Poland
Mayo Clinic · USUniversity of Rochester · US

Funding

The Immunogenetics of Measles ImmunityR01AI033144 · NIAID · MAYO CLINIC ROCHESTER · PI POLAND, GREGORY A. · 1993 to 2022
$8.1M
Immunogenetic Mechanisms of Vaccine ResponseR37AI048793 · NIAID · MAYO CLINIC ROCHESTER · PI POLAND, GREGORY A. · 2011 to 2020
$5.4M
IMMUNOGENETIC MECHANISMS OF VACCINE RESPONSER01AI048793 · NIAID · MAYO CLINIC ROCHESTER · PI POLAND, GREGORY A. · 2001 to 2010
$4.3M
Identification of Measles Class II-Restricted PeptidesR03AI053592 · NIAID · MAYO CLINIC COLL OF MEDICINE, ROCHESTER · PI OVSYANNIKOVA, INNA G · 2002 to 2003
$145k
NIAID NIH HHS AI 33144NIAID NIH HHS AI 48793NIAID NIH HHS AI 53592NIAID NIH HHS R01 AI033144NIAID NIH HHS R01 AI048793NIAID NIH HHS R03 AI053592NIAID NIH HHS R37 AI048793
6 · The paper itself

Abstract

We studied the association between class II human leukocyte antigen (HLA)-DRB1*0301 presented measles virus (MV) peptide-specific cytokine responses and DQB1 and DPB1 alleles among 313 individuals who received two doses of measles-mumps-rubella-II vaccine. The overall median IFN-gamma secretion levels (first and third quartiles) for the 19-amino acid MV phosphoprotein (MV-P)- and 14-amino acid MV nucleoprotein (MV-N)-derived peptides were 27.7 pg/ml (1.8, 109.4) and 1.9 pg/ml (-6.2, 13.0), respectively; median IL-4 secretion levels were -0.6 pg/ml (-7.1, 6.2) and 2.4 pg/ml (-3.2, 9.3), respectively. Primary statistical analyses were adjusted for previously identified DRB1 associations. A marginally significant increase in the frequency of the DQB1*0604 (p=0.02) allele was found among subjects who demonstrated detectable IL-4 levels to the MV-P peptide. Further, DPB1*0201 (p=0.02) and DPB1*1301 (p=0.09) alleles provided suggestive evidence of an association with MV-P-induced IL-4 secretion. Examination of IFN-gamma responses to MV-P and MV-N indicated that none of the individual alleles of the DQB1 and DPB1 loci were associated with peptide-induced T cell response. An increase in the frequency of DPB1*0501 (p=0.01) was found among subjects who failed to produce MV-N peptide-specific IL-4 responses. These data further confirm that HLA-DRB1 alleles are the major restriction molecules for MV-P and MV-N measles virus antigen presentation to T cells. We speculate that MV-P and MV-N peptides derived from DRB1*0301 could potentially be recognized in association with different HLA molecules, including DQB1 and DPB1; however, statistical adjustments for the effect of HLA-DR locus could potentially alter these genetic relationships. This concept provides important information supporting the use of promiscuous peptides in a peptide-based vaccine approach.

Indexed as

Polymorphism, GeneticAdolescentAllelesAmino Acid SequenceChildCytokinesFemaleHLA-DP AntigensHLA-DQ AntigensHLA-DQ beta-ChainsHLA-DR AntigensHLA-DRB1 ChainsHumansInterferon-gammaInterleukin-4MaleCytokinesHLA-DP AntigensHLA-DQ AntigensHLA-DQB1 antigenHLA-DQ beta-ChainsHLA-DR AntigensHLA-DRB1*03:01 antigenHLA-DRB1 ChainsInterferon-gammaInterleukin-4Measles-Mumps-Rubella VaccinePeptides

Identifiers

PMID16714073
PMCPMC1853367
OpenAlexW2067610268

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.